ImClone Systems, LLC
$476.4K 12 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
HEMA Biologics, LLC
HEMA Biologics, LLC reported $476,310.80 across General Payments, Research, and Ownership to 430 physicians and teaching hospitals across 454 transactions.
- $476.3K Above-median payer
- All-tracks total
- 454 Above-median volume
- Transactions
- 430 Above-median reach
- Recipients
- −$384.0K
- General Payments vs PY2023
HEMA Biologics, LLC reported $476,310.80 across all CMS Open Payments tracks (General + Research + Ownership) to 430 physicians and teaching hospitals in Program Year 2024 - ranking #775 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $276,535.80, averaging $1.1K per recipient.
How HEMA Biologics, LLC's $476.3K all-tracks total breaks down
HEMA Biologics, LLC's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
29/100
Total payments
F
14/100
Transaction volume
F
13/100
Physician reach
F
13/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer hema-biologics-llc HEMA Biologics, LLC
$476.3K · #775/1,925 · 0.0% industry · PY2024
- TOT $476.3K
- RANK #775
- SHARE 0.0%
- TXN 454
- RCP 430
- CAT 6
- GEN $276.5K
- ΔGEN −$384.0K
- TOP1 14.8%
- PY 2024
Volume peers
Nearest volume peer: ImClone Systems, LLC ($476.4K)
HEMA Biologics, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
HEMA Biologics, LLC's CMS-reported General Payments decreased by $384.0K (−58.1%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: HEMA BIOLOGICS, LLCPY2023: HEMA BIOLOGICS, LLCPY2024: HEMA Biologics, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $660,529.56
- PY2024
- $276,535.80
What the Data Shows for HEMA Biologics, LLC
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For HEMA Biologics, LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 6 general-payment categories charted below, "Consulting Fee" is the largest at $179.8K across 40 transactions, 65.0% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads HEMA Biologics, LLC's 6-category general-payment breakdown at $179.8K, 65.0% of the reported total.
HEMA Biologics, LLC reports 6 general-payment categories - the top three are Consulting Fee (65.0%), Compensation for Services Other Than Consulting (15.7%), and Travel and Lodging (11.8%). The remaining 3 categories make up 7.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How HEMA Biologics, LLC divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $179.8K | 40 | 65.0% |
| Compensation for Services Other Than Consulting | $43.5K | 16 | 15.7% |
| Travel and Lodging | $32.6K | 147 | 11.8% |
| Food and Beverage | $14.2K | 222 | 5.1% |
| Honoraria | $6.5K | 3 | 2.3% |
| Education | $32.94 | 2 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $135,086.89 (48.8%) of $276,535.80 in this company's General Payments records across 88 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for HEMA Biologics, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Doris Quon
$41,043.72 across 55 reported transactions
- 2
Guy Young
$36,883.68 across 48 reported transactions
- 3
Maissaa Janbain
$29,120.08 across 15 reported transactions
- 4
Miguel Escobar
$14,146.62 across 14 reported transactions
- 5
Steven Pipe
$13,892.79 across 15 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
HEMA Biologics, LLC ranks #775 of 1,925 by total payments (top 40% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,173 of 1,838 by HHI (bottom 36% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Ocular Therapeutix, Inc. : $1.8M total payments, HHI 711
- Oticon Medical, LLC : $43.5K total payments, HHI 706
- Nordic Pharma, Inc. : $142.6K total payments, HHI 700
- Neurent Medical Limited : $525.6K total payments, HHI 699
- Medexus Pharma, Inc. : $75.6K total payments, HHI 698
- BK Medical Holding Company Inc. : $164.8K total payments, HHI 693
- HEMA Biologics, LLC (this company) : $276.5K total payments, HHI 691
- Precision Spine, Inc. : $802.9K total payments, HHI 690
- Kuraray America Inc. : $352.3K total payments, HHI 690
- Ascendis Pharma Inc : $470.4K total payments, HHI 686
- Distalmotion US : $620.2K total payments, HHI 685
- Maxx Orthopedics, Inc. : $96.6K total payments, HHI 683
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as HEMA Biologics, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about HEMA Biologics, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with HEMA Biologics, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Monteris Medical Corporation
$475.8K 433 recipients
Compare payment profiles
Gentuity, LLC
$477.9K 69 recipients
Compare payment profiles
Prenosis Inc.
$474.5K 46 recipients
Compare payment profiles
Cardinal Health 414 LLC
$474.5K 231 recipients
Compare payment profiles
Sixth Street Solutions, LLC
$473.8K 0 recipients
Compare payment profiles
Put this to use
HEMA Biologics, LLC ranks #775 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just HEMA Biologics, LLC. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.